Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome.

CONTEXT Deficits in cerebral glucose utilization have been identified in patients with cognitive dysfunction attributed to various disease processes, but their prognostic and diagnostic value remains to be defined. OBJECTIVE To assess the sensitivity and specificity with which cerebral metabolic patterns at a single point in time forecast subsequent documentation of progressive dementia. DESIGN, SETTING, AND PATIENTS Positron emission tomography (PET) studies of [(18)F]fluorodeoxyglucose in 146 patients undergoing evaluation for dementia with at least 2 years' follow-up for disease progression at the University of California, Los Angeles, from 1991 to 2000, and PET studies in 138 patients undergoing evaluation for dementia at an international consortium of facilities, with histopathological diagnoses an average of 2.9 years later, conducted from 1984 to 2000. MAIN OUTCOME MEASURES Regional distribution of [(18)F]fluorodeoxyglucose in each patient, classified by criteria established a priori as positive or negative for presence of a progressive neurodegenerative disease in general and of Alzheimer disease (AD) specifically, compared with results of longitudinal or neuropathologic analyses. RESULTS Progressive dementia was detected by PET with a sensitivity of 93% (191/206) and a specificity of 76% (59/78). Among patients with neuropathologically based diagnoses, PET identified patients with AD and patients with any neurodegenerative disease with a sensitivity of 94% and specificities of 73% and 78%, respectively. The negative likelihood ratio of experiencing a progressive vs nonprogressive course over the several years following a single negative brain PET scan was 0.10 (95% confidence interval, 0.06-0.16), and the initial pattern of cerebral metabolism was significantly associated with the subsequent course of progression overall (P<.001). CONCLUSION In patients presenting with cognitive symptoms of dementia, regional brain metabolism was a sensitive indicator of AD and of neurodegenerative disease in general. A negative PET scan indicated that pathologic progression of cognitive impairment during the mean 3-year follow-up was unlikely to occur.

[1]  J. Morris,et al.  Current concepts in the pathogenesis of Alzheimer's disease. , 1997, The American journal of medicine.

[2]  K Herholz,et al.  FDG PET and Differential Diagnosis of Dementia , 1995, Alzheimer disease and associated disorders.

[3]  B. Reisberg,et al.  Positron Emission Tomography in the Study of Aging and Senile Dementia , 1980, Neurobiology of Aging.

[4]  R. Ernst,et al.  The US economic and social costs of Alzheimer's disease revisited. , 1994, American journal of public health.

[5]  J. Haxby Resting state regional cerebral metabolism in dementia of the Alzheimer type , 1990 .

[6]  D. Benson,et al.  Positron emission computed tomography in the diagnosis of dementia. , 1981, Transactions of the American Neurological Association.

[7]  G. Samsa,et al.  Likelihood ratios with confidence: sample size estimation for diagnostic test studies. , 1991, Journal of clinical epidemiology.

[8]  J. Mazziotta,et al.  Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[9]  Richard S. J. Frackowiak,et al.  The use of positron emission tomography in the clinical assessment of dementia. , 1992, Seminars in nuclear medicine.

[10]  N. Foster,et al.  Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease , 1997, Annals of neurology.

[11]  F. Fazio,et al.  Impairment of Neocortical Metabolism Predicts Progression in Alzheimer’s Disease , 1999, Dementia and Geriatric Cognitive Disorders.

[12]  D. Evans,et al.  Estimated prevalence of Alzheimer's disease in the United States. , 1990, The Milbank quarterly.

[13]  G. Alexander,et al.  The neurometabolic landscape of cognitive decline: in vivo studies with positron emission tomography in Alzheimer's disease. , 2000, International journal of psychophysiology : official journal of the International Organization of Psychophysiology.

[14]  Michael E. Phelps,et al.  Clinical Value of Neuroimaging in the Diagnosis of Dementia. Sensitivity and Specificity of Regional Cerebral Metabolic and Other Parameters for Early Identification of Alzheimer's Disease. , 1999, Clinical positron imaging : official journal of the Institute for Clinical P.E.T.

[15]  S. Folstein,et al.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.

[16]  M J de Leon,et al.  Topography of cross-sectional and longitudinal glucose metabolic deficits in Alzheimer's disease. Pathophysiologic implications. , 1992, Archives of neurology.

[17]  T Jones,et al.  Regional cerebral oxygen supply and utilization in dementia. A clinical and physiological study with oxygen-15 and positron tomography. , 1981, Brain : a journal of neurology.

[18]  J. Hoffman,et al.  FDG PET imaging in patients with pathologically verified dementia. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[19]  Positron and single photon emission tomography in the differential diagnosis of dementia , 1990 .

[20]  N. Foster,et al.  Alzheimer's disease , 1983, Neurology.

[21]  D Comar,et al.  Differential diagnosis of Alzheimer's disease with PET. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[22]  D. Silverman,et al.  Evaluating dementia using PET: how do we put into clinical perspective what we know to date? , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[23]  H. Chui,et al.  Evaluation of dementia: A systematic study of the usefulness of the American Academy of Neurology's Practice Parameters , 1997, Neurology.